Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
Norbinaltorphimine (NorBNI), guanidinonaltrindole, and atrans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine (JDTic) are selective kappa opioid receptor (KOR) antagonists having very long durations of action in vivo despite binding non-covalently in vitro and having only moderately high affinities. Consistent with this, we found that antagonist treatment significantly reduced the subsequent analgesic response of mice to the KOR agonist U50,488 in the tail-withdrawal assay for 14-21 days. Receptor protection assays were designed to distinguish between possible explanations for this anomalous effect, and we found that mice pretreated with the readily reversible opioid antagonists naloxone or buprenorphine before norBNI responded strongly in the tail-flick analgesia assay to a subsequent challenge with U50,488 1 week later. Protection by a rapidly cleared reagent indicates that norBNI did not persist at the site of action. In vitro binding of [(3)H]U69,593 to KOR showed that K(d) and Bmax values were not significantly affected by prior in vivo norBNI exposure, indicating that the agonist binding site was intact. Consistent with the concept that the long-lasting effects might be caused by a functional disruption of KOR signaling, both norBNI and JDTic were found to stimulate c-Jun N-terminal kinase (JNK) phosphorylation in HEK293 cells expressing KOR-GFP but not in untransfected cells. Similarly, norBNI increased phospho-JNK in both the striatum and spinal cord in wild type mice but not in KOR knock-out mice. Pretreatment of mice with the JNK inhibitor SP600125 before norBNI attenuated the long acting antagonism. Together, these results suggest that the long duration KOR antagonists disrupt KOR signaling by activating JNK.
Bruchas
Michael R
MR
Department of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
Yang
Tao
T
Schreiber
Selena
S
Defino
Mia
M
Kwan
Steven C
SC
Li
Shuang
S
Chavkin
Charles
C
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology; D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D010766:Phosphorylation; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D015398:Signal Transduction
D018712:Analgesics, Non-Narcotic; D000873:Anthracenes; D004791:Enzyme Inhibitors; D017473:Receptors, Opioid, kappa; C432165:pyrazolanthrone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D048031:JNK Mitogen-Activated Protein Kinases
Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609
16064136
Behav Pharmacol. 1995 Dec;6(8):815-820
11224385
Eur J Pharmacol. 2000 May 12;396(1):49-52
10822054
J Med Chem. 2004 Feb 12;47(4):1070-3
14761209
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6
11717429
Prog Clin Biol Res. 1990;328:65-8
2154820
Trends Pharmacol Sci. 2001 Jul;22(7):368-76
11431032
Pharmacol Rev. 1996 Dec;48(4):567-92
8981566
J Pharmacol Exp Ther. 1997 Aug;282(2):676-84
9262330
Biochem Biophys Res Commun. 1998 Feb 4;243(1):41-6
9473476
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32
17303418
J Pharmacol Exp Ther. 1999 Dec;291(3):1113-20
10565831
J Neurochem. 2000 Feb;74(2):564-73
10646507
Mol Pharmacol. 2006 Oct;70(4):1264-70
16870886
J Biol Chem. 2006 Jun 30;281(26):18081-9
16648139
J Biol Chem. 2004 Jan 16;279(3):1810-8
14597630
J Pharmacol Exp Ther. 1982 Oct;223(1):157-62
6288917
Life Sci. 1987 Mar 30;40(13):1287-92
2882399
J Neurosci. 2006 Mar 29;26(13):3551-60
16571763
J Pharmacol Exp Ther. 1993 Dec;267(3):1269-76
8263790
Eur J Neurosci. 2002 Nov;16(9):1705-12
12431223
Neurochem Res. 1996 Nov;21(11):1277-85
8947917
Psychopharmacology (Berl). 2005 Nov;183(1):118-26
16184376
Bioorg Med Chem Lett. 2005 Jun 2;15(11):2761-5
15869877
J Med Chem. 2003 Jul 3;46(14):3127-37
12825951
Psychopharmacology (Berl). 1994 Jul;115(3):311-9
7871070
J Biol Chem. 2003 Sep 5;278(36):34631-40
12815037
Nat Neurosci. 1999 Feb;2(2):151-6
10195199
J Med Chem. 1987 Feb;30(2):238-9
3027336
Eur J Pharmacol. 1992 May 14;215(2-3):345-8
1327807
J Med Chem. 2001 Aug 16;44(17):2687-90
11495579
J Biol Chem. 2005 Jul 29;280(30):27662-9
15944153
J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
16803859
Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101
15023353
J Pharmacol Exp Ther. 1992 Mar;260(3):1237-43
1312164
J Pharmacol Exp Ther. 1988 Jul;246(1):255-8
2839664
Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9
15464069
J Pharmacol Exp Ther. 2004 Jul;310(1):301-10
14996948
AAPS J. 2005 Oct 27;7(3):E704-22
16353947
Science. 1982 Jan 22;215(4531):413-5
6120570
J Neurosci. 2003 Jul 2;23(13):5674-83
12843270
J Neurochem. 1998 Feb;70(2):635-45
9453557
J Pharmacol Exp Ther. 1984 Apr;229(1):118-26
6142942
J Med Chem. 2007 Jul 26;50(15):3596-603
17580847
J Pharmacol Exp Ther. 2003 Apr;305(1):323-30
12649385
Psychopharmacology (Berl). 2002 Oct;163(3-4):412-9
12373442
Trends Pharmacol Sci. 2004 Apr;25(4):186-92
15063082